News

General availability for applicants begins on June 3

As new cancer drugs with promising efficacy but brutal costs enter the market, providers, payers and manufacturers are strategizing new payment approaches

Heightened concern over adherence and product stability may win over more pharma clients

Mevion's compact S250 unit bids to change the economics of radiation oncology

Meanwhile, industry asset shuffling is at record levels

Obama's Precision Medicines initiative could re-open the door

Use of state-of-the-art software, combined with benchmarking and active oversight, fills this gap

Novo Nordisk is tagged as the only 'high performer'

Sandoz is first on the market with the MS drug, currently worth around $3 billion in the US

Company targets evolving regenerative medicine market

$4.8-billion deal follows UPS' failed effort in 2013

Partners with EHR vendor PointClickCare to access 10,000 senior-care facilities in North America

Leading copay-coupon provider expands its patient services with private equity help

Service closes the loop on managing specialty-pharmaceutical therapy regimens

Do you know your J codes?

AstraZeneca's Seroquel XR sample kit takes top honors

If the count of working sales reps is rising, who will those reps be able to visit?

$12.8-billion acquisition will bring 1 billion precriptions/year under one PBM's management

Creation of a holding company streamlines future acquisitions; focus is on specialty drug services

National association wins oversight for the valuable top-level domain (TLD), begins approving online pharmacies' use of it

Veeva OpenKey database service will provide a standardized quality level for global healthcare-provider reference data

Office will serve Shanghai and Suzhou life sciences clients

But a majority of dispensers (pharmacies) are not yet preparing for their July 1 deadline

Top 25 medical-benefit drugs showed an 8% increase over prior year

Besides specialty pharmaceutical pricing, the cost of compounded drugs is highlighted

Company wins $10 million in venture capital as it lines up key life sciences service providers

Literature survey from Altarum Institute finds a growing body of evidence of value

IHS, hereafter to be known as ARxIUM, will expand its injectable-compounding business to include oral solids